Technical Analysis for CMVLF - Cellectis Romainvil

Grade Last Price % Change Price Change
grade F 11.8449 0.47% 0.0549
CMVLF closed up 0.47 percent on Friday, September 20, 2019, on 1 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical CMVLF trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction 0.47%
Wide Bands Range Expansion 0.47%
Gapped Down Weakness 0.47%
Oversold Stochastic Weakness 0.47%
Slingshot Bearish Bearish Swing Setup -6.14%
Stochastic Buy Signal Bullish -6.14%

Older signals for CMVLF ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Cellectis S.A., a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL). The company's products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-ALL. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc; Les Laboratoires Servier SAS; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia, as well as a partnership agreement with the Wyss Institute for Biologically Inspired Engineering at Harvard University. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Biotechnology RTT Cancer Immunotherapy Cancer Immunotherapy Immunotherapies Leukemia Multiple Myeloma Acute Myeloid Leukemia Acute Lymphoblastic Leukemia University Of Texas Agricultural Biotechnology Texas Md Anderson Cancer Center Hematologic Malignancies Immuno Oncology Products Liquid Tumors Tumors Of The Hematopoietic And Lymphoid Tissues
Is CMVLF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 36.56
52 Week Low 11.29
Average Volume 18,404
200-Day Moving Average 0.0
50-Day Moving Average 18.4059
20-Day Moving Average 14.6212
10-Day Moving Average 13.0655
Average True Range 1.0098
ADX 21.47
+DI 35.4219
-DI 58.5817
Chandelier Exit (Long, 3 ATRs ) 17.5606
Chandelier Exit (Short, 3 ATRs ) 14.3194
Upper Bollinger Band 19.1746
Lower Bollinger Band 10.0678
Percent B (%b) 0.2
BandWidth 62.284901
MACD Line -1.8825
MACD Signal Line -1.8079
MACD Histogram -0.0747
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.8449
Resistance 3 (R3) 11.8449 11.8449 11.8449
Resistance 2 (R2) 11.8449 11.8449 11.8449 11.8449
Resistance 1 (R1) 11.8449 11.8449 11.8449 11.8449 11.8449
Pivot Point 11.8449 11.8449 11.8449 11.8449 11.8449
Support 1 (S1) 11.8449 11.8449 11.8449 11.8449 11.8449
Support 2 (S2) 11.8449 11.8449 11.8449 11.8449
Support 3 (S3) 11.8449 11.8449 11.8449
Support 4 (S4) 11.8449